The FDA has confirmed that it wants Dynavax (DVAX) to collect safety information from more...

|About: Dynavax Technologies Corp... (DVAX)|By:, SA News Editor

The FDA has confirmed that it wants Dynavax (DVAX) to collect safety information from more patients for the company's Heplisav hepatitis B vaccine, although the agency also acknowledged an advisory committee's endorsement of the drug's "demonstrated immunogenicity." The extra information will facilitate a review for using Heplisav in adults aged 18-80. Dynavax's shares crater 26%. (PR)